

## RECORDATI: PUBLICATION OF THE SLATE OF CANDIDATES FOR THE APPOINTMENT OF DIRECTOR OF THE COMPANY BY A GROUP OF ASSET MANAGEMENT COMPANIES AND INSTITUTIONAL INVESTORS

Milan, 11 January 2019 – Pursuant to art. 144-octies, paragraph 1 of Consob's Regulation 11971/1999 ("Issuers' Regulations") and with reference to the Ordinary General Meeting of the Shareholders to be held on 5<sup>th</sup> February 2019 in a single call, RECORDATI S.p.A. informs that, as of today, the slate for the appointment of the Board of Directors filed by a group of asset management companies and institutional investors - which collectively own about 1.303% of RECORDATI S.p.A.'s share capital (Slate No. 2) - is available to the public at the Company's registered offices, on the "1info" storage mechanism ([www.1info.it](http://www.1info.it)) and on the Company's website ([www.recordati.it](http://www.recordati.it) - section Investors, Shareholders' Meetings).

Please note that the above mentioned list is available jointly with the relevant documentation requested by law and by the Company's By-laws.

Furthermore, please be reminded that the slate filed by the majority shareholder FIMEI S.p.A. on 7 January 2019 (Slate No. 1) has already been made available to public by the same means indicated above.

*Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2017 was € 1,288.1 million, operating income was € 406.5 million and net income was € 288.8 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

### Investor Relations

Marianne Tatschke  
(39)0248787393  
e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

### Media Relations

Studio Noris Morano  
(39)0276004736, (39)0276004745  
e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.  
REG. IMP. MILANO N. 00748210150  
CODICE FISCALE/P.IVA 007482210150  
R.E.A. MILANO N. 401832